European equities closed lower on Tuesday as investors remained cautious over the timing of the Fed's reduction of its stimulus program.» Read More
CHICAGO, Dec 9- There is a growing consensus that U.S. stocks, as well as stocks around the world, are going to catch a tailwind going into 2014.. The Vanguard Total World Stock Index ETF owns more than 5,000 stocks, but has its top holdings in mega-cap American companies like Apple Inc, Exxon Mobil Corp and Google Inc..
Dec 8- An experimental AbbVie Inc drug for leukemia controlled or eliminated signs of the disease in more than 80 percent of patients who had failed to benefit from previous treatments, an unprecedented finding that could spur use of the medicine for other cancers, researchers said.
Dec 3- Patients who are being treated for a leading cause of blindness among the elderly might be able to scale back on eye injections if trials confirm the potential of an eye drop being developed by a small New York- based company.
Nov 27- President Barack Obama signed a bill into law on Wednesday that gives U.S. health regulators greater oversight of bulk pharmaceutical compounding and strengthens their ability to track drugs through the distribution pipeline.
With Washington's debt battle over, markets will quickly shift focus to earnings and how much the government shutdown actually impacted the economy.
Andrew Weiss, head of pharma and biotech research at Vontobel, says Roche's plan reflects the Swiss pharmaceutical giant's strong pipeline.
German airline Deutsche Lufthansa announced its largest-ever aircraft order on Thursday, worth 14 billion euros ($19.0 billion).
Verizon Communications priced a massive bond sale on Wednesday, offering $49 billion worth of debt.
The FDA is expected to decide on whether to fast track Perjeta for early treatment of breast cancer by Oct. 31.
As resources move to other areas, cardiologists fear the battle against heart disease could stall after advances marked by critical drugs to lower cholesterol and blood pressure.
The investment bank highlights eight industry themes it describes as "creative destruction" - trends that make it necessary for companies to either "adapt or die."
European shares closed lower on Thursday with investor confidence curbed by a mixed bag of earnings from major companies and concerns about slowing growth in China.
Daniel O'Day, CEO of Roche, talks about the company's results for the first half of the year and sales of its new breast cancer drugs.
Daniel O'Day, CEO of Roche's pharma unit, declines to comment on Alexion deal talks, but says the company is keen on incorporating innovations into its portfolio.
Daniel O'Day, the CEO of Roche's pharmaceuticals unit declined to comment on market rumors that the Swiss drug maker is about to bid for Alexion, but told CNBC that the company continues to look for new innovations.
Andrew Weiss, head of pharma and biotech research at Vontobel, , talks about Novartis' quarterly results and outlook and says the company will remain under pressure for the next few quarters.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Some of the names on the move ahead of the open.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.